Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma

Rummel, Mathias; Chow, Kai Uwe; Karakas, Tunca; Jäger, Elke; Mezger, J.; Grünhagen, Ulrich von; Schalk, K. P.; Burkhard, Oswald; Hansmann, M. L.; Ritzel, H; Bergmann, Lothar; Hoelzer, Dieter; Mitrou, Paris S.

doi:10.1016/s0959-8049(02)00143-0

Cited by 43 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is currently used in treatment of indolent lymphoid malignancies, including hairy cell leukemia, chronic lymphocytic leukemia and low-grade lymphoma (1)(2)(3)(4). It was also reported to be effective as an immunosuppressive drug (5).…”

Section: Introductionmentioning

confidence: 99%

Lipid raft disruption prevents apoptosis induced by 2-chloro-2′-deoxyadenosine (Cladribine) in leukemia cell lines

et al. 2006

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Lipid raft disruption prevents apoptosis induced by 2-chloro-2′-deoxyadenosine (Cladribine) in leukemia cell lines

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Future approaches to improving the CR rate and remission duration with front-line 2-CdA therapy may involve combination therapy with other chemotherapeutic agents. Several Phase I and II trials have piloted combinations of 2-CdA with mitoxantrone, [40][41][42] cyclophosphamide, 43,44 and chlorambucil. 45 However, in those initial trials, response rates from 28.5% to 90% (CR rate, 7.1-44%) appear similar to single-agent trials, and toxicities may be increased.…”

Section: Discussionmentioning

confidence: 99%

Prolonged follow‐up after initial therapy with 2‐chlorodeoxyadenosine in patients with indolent non‐Hodgkin lymphoma

Blum¹,

Johnson²,

Niedzwiecki³

et al. 2006

Cancer

View full text Add to dashboard Cite

A H2O/dimethyl sulfoxide(DMSO) mixture was used as the coagulation bath for the wet‐spun process of acrylonitrile/ammonium itaconate copolymers fibers. Diffusion coefficient of DMSO in the protofibers prepared by acrylonitrile/ammonium itaconate copolymers was determined. It has been found that diffusion coefficient of DMSO outflow of the protofibers prepared by acrylonitrile/ammonium itaconate copolymers synthesized by the solution polymerization is highest compared with those of acrylonitrile/ammonium itaconate copolymers synthesized by H2O/DMSO mixture suspension polymerization and the aqueous suspension polymerization. With an increase of copolymer concentration in the dope, diffusion coefficient of DMSO decreases continuously. Diffusion coefficient of DMSO increases along with the bath temperature, but the changes of diffusion coefficient values are less prominent as temperature goes beyond 60°C. When DMSO concentration in the coagulation bath was 55 wt %, the value of the diffusion coefficient of DMSO was minimal. Diffusion coefficient of H2O increases with the jet stretch minus ratio increasing. © 2006 Wiley Periodicals, Inc. J Appl Polym Sci 100: 4447–4451, 2006

show abstract

“…Studies evaluating cladribine in combination with cyclophosphamide, mitoxantrone, or rituximab reported superior response rates compared with single-agent cladribine (Table 2). [37][38][39][40][41][42][43][44][45] However, as is often the case in studies with indolent lymphomas, there were no statistical differences in overall survival (OS). Toxicities were typically hematologic and infectious, and were generally not severe.…”

Section: Combination Therapy In Previously Treated Indolent Nhlmentioning

confidence: 97%

“…45 In another trial, of 18 MCL patients treated with combination cladribine and mitoxantrone, all responded (8 patients with a CR) and had a 24-month median duration of response. 41 Among a different group of 9 MCL patients given cladribine in combination with cyclophosphamide and rituximab, 6 patients responded with 2 obtaining a CR. 43 These results demonstrate that cladribine is highly active both as a single agent and as a component of combination therapy for MCL patients.…”

Section: MCLmentioning

confidence: 99%

Beyond hairy cell: the activity of cladribine in other hematologic malignancies

Sigal

Miller

Schram

et al. 2010

Blood

View full text Add to dashboard Cite

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma

Cited by 43 publications

References 29 publications

Lipid raft disruption prevents apoptosis induced by 2-chloro-2′-deoxyadenosine (Cladribine) in leukemia cell lines

Lipid raft disruption prevents apoptosis induced by 2-chloro-2′-deoxyadenosine (Cladribine) in leukemia cell lines

Prolonged follow‐up after initial therapy with 2‐chlorodeoxyadenosine in patients with indolent non‐Hodgkin lymphoma

Beyond hairy cell: the activity of cladribine in other hematologic malignancies

Contact Info

Product

Resources

About